Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.

Inclusion Criteria Patients must have: Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay. HIV RNA measurement of > 5,000 copies/ml within 3 weeks of baseline visit. Signed, informed consent from parent or legal guardian for patients less than 18 years of age. Access to a refrigerator for storing study drug. Prior Medication: Allowed: Anti-HIV therapy other than protease inhibitor therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Evidence of acute infection, as measured by vital signs, physical examination, 12-lead electrocardiogram and laboratory assessments. Condition that may obscure the proper observation of the safety or activity of the treatment regimens. Concurrent Medication: Excluded: Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam, zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil, terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine, propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin. Anti-retroviral therapy initiated prior to study entry. Any other medication, including over-the-counter medicine and alcohol, taken without the permission of the primary investigator. Patients with the following prior conditions are excluded: History of significant drug hypersensitivity. History of psychiatric illness that would preclude compliance with the protocol. Prior enrollment in this study. Prior Medication: Excluded: Investigational drugs within 30 days prior to drug administration. Prior treatment with licensed or investigational HIV protease inhibitor. 1. Active substance abuse. Positive urine screen for recreational drugs. NOTE: The presence of cannabis is not exclusionary unless the investigator believes its use will interfere with patient compliance.